Characterization of human anti-EpCAM antibodies for developing an antibody-drug conjugate

表征人类抗 EpCAM 抗体以开发抗体-药物偶联物

阅读:10
作者:Hiroyuki Satofuka #, Yayan Wang #, Kyotaro Yamazaki #, Shusei Hamamichi, Takeshi Fukuhara, Abdur Rafique, Nana Osako, Iori Kanazawa, Takeshi Endo, Naomi Miyake, Kazuhisa Honma, Yuichi Nagashima, Genki Hichiwa, Kazuto Shimoya, Satoshi Abe, Takashi Moriwaki, Yasufumi Murakami, Xu Gao, Hiroyuki Kugoh, 

Abstract

We previously generated fully human antibody-producing TC-mAb mice for obtaining potential therapeutic monoclonal antibodies (mAbs). In this study, we investigated 377 clones of fully human mAbs against a tumor antigen, epithelial cell adhesion molecule (EpCAM), to determine their antigen binding properties. We revealed that a wide variety of mAbs against EpCAM can be obtained from TC-mAb mice by the combination of epitope mapping analysis of mAbs to EpCAM and native conformational recognition analysis. Analysis of 72 mAbs reacting with the native form of EpCAM indicated that the EpCL region (amino acids 24-80) is more antigenic than the EpRE region (81-265), consistent with numerous previous studies. To evaluate the potential of mAbs against antibody-drug conjugates, mAbs were directly labeled with DM1, a maytansine derivative, using an affinity peptide-based chemical conjugation (CCAP) method. The cytotoxicity of the conjugates against a human colon cancer cell line could be clearly detected with high-affinity as well as low-affinity mAbs by the CCAP method, suggesting the advantage of this method. Thus, this study demonstrated that TC-mAb mice can provide a wide variety of antibodies and revealed an effective way of identifying candidates for fully human ADC therapeutics.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。